Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

611

Next Previous
Drug Profile

611

Alternative Names: Anti-IL4Ra antibody; Recombinant humanized anti-IL-4 receptor alpha IgG4 monoclonal antibody

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3SBio
  • Developer 3SBio; Sunshine Guojian Pharmaceutical
  • Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor alpha subunit antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Chronic obstructive pulmonary disease
  • No development reported Eczema

Most Recent Events

  • 05 Aug 2025 Phase-III clinical trials in Atopic dermatitis (In adolescents) in China (SC) (NCT07042126)
  • 16 Jul 2025 Phase-III clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in China (SC) (NCT07039669)
  • 26 Jun 2025 Sunshine Guojian Pharmaceutical plans phase III trial in Chronic obstructive pulmonary disease in China in July 2025 (SC) (NCT07039669)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top